Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 2/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18611836 | 0.81 | TLR8 (0.37) | DYRK1ANOTUMAHRTTKTYR | |
| SCHEMBL20088501 | 0.81 | NAMPT (0.43) | NAMPTDYRK1AAHRTTKALDH1A1 | |
| SCHEMBL10220047 | 0.80 | AHR (0.47) | NAMPTAHRALDH1A1KDM4ENPC1 | |
| SCHEMBL21929912 | 0.80 | AHR (0.53) | NAMPTDYRK1AAHRALDH1A1MEN1 | |
| SCHEMBL23692928 | 0.80 | PIK3CG (0.42) | DYRK1ANOTUMALDH1A1MEN1NPC1 | |
| SCHEMBL20094507 | 0.80 | AHR (0.44) | NAMPTAHRALDH1A1KDM4ENPC1 | |
| SCHEMBL22675440 | 0.77 | PDE10A (0.32) | NAMPTDYRK1ANOTUMFFAR1LMNA | |
| SCHEMBL798669 | 0.73 | AHR (0.33) | NAMPTAHRALDH1A1KDM4ENPC1 | |
| SCHEMBL6900236 | 0.72 | JAK2 (0.46) | NAMPTNPSR1ALDH1A1KDM4EMEN1 | |
| SCHEMBL21929765 | 0.71 | NAMPT (0.41) | NAMPTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20220127260-A1 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127260-A1 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | NAMPT 1143/4885DYRK1A 399/4885NOTUM 4022/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | NAMPT 1325/4885DYRK1A 3180/4885NOTUM 3567/4885 |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | NAMPT 1143/4885DYRK1A 399/4885NOTUM 4022/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | NAMPT 1361/4885DYRK1A 3782/4885NOTUM 3656/4885 |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | CSF1R, CSF3R, MSR1 | NAMPT 2293/4885DYRK1A 1640/4885NOTUM 3682/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | NAMPT 1839/4885DYRK1A 3492/4885NOTUM 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.